Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $143M | $284M | $799M | $883M | $289M | $259M | $186M |
| Revenue growth | — | 98.5% | 181.3% | 10.5% | -67.3% | -10.3% | -28.3% |
| Gross profit | — | — | — | — | $140M | $108M | $34.0M |
| Gross margin | — | — | — | — | 48.5% | 41.8% | 18.3% |
| Operating income | $24.0M | $120M | $555M | $574M | -$31.6M | -$236M | -$215M |
| Operating margin | 16.8% | 42.2% | 69.4% | 65.0% | -11.0% | -90.9% | -115.9% |
| Net income | -$4.47M | $89.0M | $182M | $220M | -$119M | -$145M | -$131M |
| Net margin | -3.1% | 31.3% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (diluted) | -$0.03 | $2.36 | $1.56 | $1.67 | -$0.90 | -$1.05 | -$0.90 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.1M | $152M | $369M | $536M | $126M | $7.46M | -$57.6M |
| Capital expenditures | $17.1M | $25.4M | $14.8M | $17.1M | $65.6M | $29.7M | $13.1M |
| Free cash flow | $6.97M | $127M | $354M | $519M | $60.7M | -$22.2M | -$70.7M |
| Share buybacks | $0.00 | $33.7M | $0.00 | $0.00 | — | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.7M | $236M | $551M | $632M | $575M | $322M | $217M |
| Total assets | — | $1.27B | $1.92B | $2.28B | $1.49B | $1.01B | $771M |
| Total liabilities | — | $1.12B | $1.37B | $1.38B | $698M | $431M | $398M |
| Long-term debt | — | $529M | $525M | $522M | $519M | $290M | $286M |
| Shareholders' equity | $145M | $88.5M | $315M | $545M | $417M | $325M | $212M |
| Retained earnings | — | $854K | $185M | $405M | $286M | $141M | $10.1M |
| Shares (wtd avg diluted) | 254M | 28.9M | 258M | 255M | 132M | 138M | 144M |
Every figure is extracted from MARAVAI LIFESCIENCES HOLDINGS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.